Pharma BD Deal Intelligence
Jazz Pharmaceuticals' $1.5B acquisition of Celator Pharmaceuticals gave Jazz sole ownership of Celator's liposomal chemotherapy pipeline, cementing Jazz's push into oncology beyond its hematology base.
Jazz Pharmaceuticals to acquire Celator for $1.5B gaining VYXEOS first product to show OS improvement in AML.
entered into a definitive Agreement and Plan of Merger (the Merger Agreement ) with Celator Pharmaceuticals, Inc.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
entered into a definitive Agreement and Plan of Merger (the Merger Agreement ) with Celator Pharmaceuticals, Inc.
Rylaze (recombinant Erwinia asparaginase, asparaginase erwinia chrysanthemi-rywn) serves ALL/LBL patients with hypersensitivity to E. coli-derived asparaginase. The ALL backbone is multi-MOA; Rylaze competes inside the asparaginase slot while coexisting with other drug classes. Asparaginase class: pegaspargase (Oncaspar, Servier) is the first-line long-acting E. coli formulation; calaspargase pegol (Asparlas, Servier) is approved for pediatric/young-adult ALL with every-3-week dosing; native Erwinia asparaginase (Erwinase, Porton Biopharma) historically filled the hypersensitivity niche but had supply disruptions that opened the door for Rylaze's 2021 FDA approval. Bispecific T-cell engager: blinatumomab (Blincyto, Amgen) is approved for MRD-positive and R/R B-cell ALL; generated $861M in 2023 Amgen sales. Antibody-drug conjugate: inotuzumab ozogamicin (Besponsa, Pfizer) is approved in R/R CD22+ B-cell ALL. CAR-T: tisagenlecleucel (Kymriah, Novartis) and brexucabtagene autoleucel (Tecartus, Gilead/Kite) serve R/R pediatric and adult B-ALL. TKIs: imatinib/dasatinib/ponatinib are standard in Ph+ ALL. Rylaze's franchise thesis is durable because it is the only FDA-approved non-E. coli-derived asparaginase post-Erwinase discontinuation, and pegaspargase/calaspargase hypersensitivity reactions create a persistent switch pool estimated at 15-20% of treated patients.
Celator's 'Solid tumors' pre-acquisition pipeline (CPX-1 irinotecan/floxuridine, various liposomal combinations) did not advance under Jazz. The solid-tumor CombiPlex platform was not pursued post-Vyxeos AML approval. No competitive set to author; recommend archiving this indication row as a pre-deal pipeline stub.
Vyxeos (daunorubicin/cytarabine liposomal, CPX-351) is approved for newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC), a high-risk subset. Liposomal cytotoxic (direct comparator): Vyxeos itself is differentiated by a fixed 5:1 molar ratio encapsulated formulation of standard 7+3 components. Targeted small molecules are the main franchise threat. BCL-2 inhibitor: venetoclax (Venclexta, AbbVie/Genentech) + azacitidine is the dominant frontline regimen in unfit/elderly AML and continues expanding into fit patients; generated $2.3B+ in 2023 AbbVie sales. FLT3 inhibitors: midostaurin (Rydapt, Novartis), gilteritinib (Xospata, Astellas), and quizartinib (Vanflyta, Daiichi, FDA-approved July 2023) serve FLT3-mutant AML. IDH inhibitors: ivosidenib (Tibsovo, Servier) for IDH1 and enasidenib (Idhifa, BMS) for IDH2. Menin inhibitor: revumenib (Revuforj, Syndax, FDA-approved November 2024) for KMT2A-rearranged acute leukemia. Hypomethylating agents: azacitidine (Vidaza, BMS/generic) and decitabine/cedazuridine (Inqovi, Otsuka/Taiho) anchor MDS and unfit AML. Vyxeos retains a specific niche in fit t-AML/AML-MRC patients where anthracycline-based induction remains standard, but venetoclax combinations and mutation-targeted agents increasingly divert frontline patients away from intensive chemotherapy.
Jazz/Celator Vyxeos (liposomal daunorubicin/cytarabine) is FDA-approved for AML only (t-AML and AML-MRC, 2017). The 'Solid tumors and hematologic malignancies' label is an aggregate; primary competitive context belongs on the AML row: Venclexta+azacitidine (AbbVie/Genentech), Revuforj (revumenib, Syndax; menin inhibitor approved 2024), and standard 7+3 induction. Celator's pre-acquisition pipeline included CPX-1 (solid tumors) and CPX-8 (lymphoma) but none advanced post-acquisition. Jazz has not initiated new Vyxeos indications beyond AML.
Zanidatamab (Ziihera) is a HER2-directed biparatopic bispecific antibody approved by the FDA November 2024 for previously treated HER2-positive (IHC 3+) unresectable or metastatic biliary tract cancer (BTC). The HER2-targeted competitive set varies by tumor type but splits into four MOA groups. HER2 monoclonal antibodies: trastuzumab (Herceptin, Roche) and biosimilars are the foundational agent in HER2+ breast and gastroesophageal adenocarcinoma; pertuzumab (Perjeta, Roche) is used in HER2+ breast. Roche reported 2023 Herceptin sales of approximately CHF 1.4B (eroded by biosimilars) and Perjeta at CHF 4.0B. HER2 antibody-drug conjugates: trastuzumab deruxtecan (Enhertu, Daiichi/AstraZeneca) is the dominant late-line agent with tumor-agnostic HER2+ FDA approval (April 2024) and approximately $2.6B 2023 AstraZeneca revenue; trastuzumab emtansine (Kadcyla, Roche) serves residual-disease HER2+ breast. HER2 tyrosine kinase inhibitors: tucatinib (Tukysa, Pfizer/Seagen), lapatinib (Tykerb, Novartis/generic), and neratinib (Nerlynx, Puma) target HER2+ breast and metastatic CRC (tucatinib + trastuzumab in HER2+ mCRC, FDA-approved 2023). Other bispecifics: zenocutuzumab (Bizengri, Merus) targets NRG1+ tumors but overlaps in HER-family biology. Ziihera's BTC niche is defended (first approved HER2-targeted therapy in BTC), but Enhertu's tumor-agnostic label and breast/gastric depth make it the dominant franchise threat.
The broad epilepsy market is mature, generic-dominated, and MOA-diverse; any new entrant like JZP053 (SAN2355) competes at franchise launch pricing against pennies-per-pill generics plus a handful of branded holdouts. Sodium channel blockers: lamotrigine (Lamictal, GSK/generic), carbamazepine (Tegretol, Novartis/generic), oxcarbazepine (Trileptal, Novartis/generic), eslicarbazepine (Aptiom, Sumitomo), and lacosamide (Vimpat, UCB/generic post-2022) anchor focal-onset treatment. SV2A modulator: levetiracetam (Keppra, UCB/generic) and brivaracetam (Briviact, UCB) are used broadly; Briviact generated approximately $527M in 2023 UCB sales. GABAergic/broad-spectrum: valproic acid (Depakote, AbbVie/generic), clobazam (Onfi, Lundbeck/generic), and perampampanel (Fycompa, Eisai) provide second-line options. Kv7 potassium-channel openers (direct MOA threat to SAN2355 if that is the target): ezogabine (Potiga, GSK) was withdrawn in 2017 over retinal toxicity, but XEN1101 (azetukalner, Xenon Pharmaceuticals, Phase 3 X-TOLE trial) is the closest next-gen Kv7 opener. Newer mechanisms: cenobamate (Xcopri, SK Life Sciences), FDA-approved 2019 for focal-onset seizures, has shown ~20% seizure-freedom in refractory patients and generated approximately $362M in 2023. Cannabidiol (Epidiolex, Jazz) is limited to specific syndromes. JZP053 must demonstrate differentiated efficacy in drug-resistant focal epilepsy versus cenobamate and azetukalner to command premium access.
Zepzelca (lurbinectedin) is FDA-approved (accelerated, June 2020) for metastatic small cell lung cancer (SCLC) with progression on/after platinum chemotherapy; Jazz reported Zepzelca 2023 net sales of approximately $305M. The SCLC second-line competitive landscape is MOA-crowded. Alkylator/DNA-binder class (Zepzelca's closest analog): topotecan (Hycamtin, Novartis/generic) is the legacy topoisomerase I inhibitor second-line standard. Anti-PD-L1 + platinum (frontline that feeds the second-line pool): atezolizumab (Tecentriq, Roche) + carboplatin/etoposide and durvalumab (Imfinzi, AstraZeneca) + platinum/etoposide are standard-of-care frontline. DLL3-targeted bispecific (emerging direct threat): tarlatamab (Imdelltra, Amgen) received FDA accelerated approval May 2024 for extensive-stage SCLC after platinum-based chemotherapy — the most significant new franchise threat to Zepzelca in the post-platinum space. PARP inhibitor combinations: olaparib (Lynparza, AstraZeneca) is in SCLC trials but not approved. Anti-Trop2 ADC: datopotamab deruxtecan (Datroway, Daiichi/AstraZeneca) is in Phase 2 SCLC trials. Ewing sarcoma (emerging indication): lurbinectedin is being studied in Phase 2; standard second-line options include irinotecan/temozolomide, vincristine/irinotecan/temozolomide (VIT), and cyclophosphamide/topotecan — no FDA-approved agent specifically for relapsed Ewing. Tarlatamab's launch is Zepzelca's primary SCLC franchise threat.
Jazz/Celator 'Multiple tumor types' is an aggregate label for Vyxeos (liposomal daunorubicin/cytarabine). Primary indication is AML (FDA-approved 2017) where competitors are Venclexta, azacitidine, Revuforj. Secondary indications under investigation at deal announcement were MDS and solid tumors (Phase 1/2 only). Split into specific indications for proper landscape.
Absence epilepsy is a generic-dominated market with T-type calcium-channel modulation as the anchoring MOA. T-type calcium channel blockers: ethosuximide (Zarontin, Pfizer/generic) remains the first-line agent and the comparator any new entrant must beat on efficacy/tolerability; it has been standard since 1960. Broad-spectrum sodium/multi-ion channel and GABAergic agents: valproic acid (Depakote, AbbVie/generic) is used when tonic-clonic seizures coexist; lamotrigine (Lamictal, GSK/generic) is a third alternative, though landmark NEJM data (Glauser 2010) established ethosuximide and valproic acid as superior to lamotrigine in childhood absence epilepsy for freedom-from-failure. SV2A modulator: levetiracetam (Keppra, UCB/generic) is commonly used off-label despite weaker evidence in typical absence. Cannabidiol-based: Epidiolex (cannabidiol, Jazz) is approved in LGS/Dravet/TSC but not specifically absence. Pipeline: soticlestat (TAK-935, Takeda) failed its Phase 3 SKYLINE trial in Dravet in 2023 but is still being evaluated in developmental and epileptic encephalopathies with absence features. A commercial lead sizing JZP047 threat must contend with pennies-per-pill generic ethosuximide as the efficacy/cost bar; premium pricing requires demonstrated superiority in refractory absence or atypical absence subpopulations.
Celator's CNS tumors pre-acquisition pipeline was early-stage and did not advance under Jazz. Jazz's CNS franchise is instead anchored by Xywav (oxybate for narcolepsy), Epidiolex (cannabidiol for LGS/Dravet/TSC), and Vyxeos (AML-only). No active CNS-tumor competitive set to author for this deal; recommend archiving as pre-deal pipeline stub.
Epidiolex/Epidyolex (cannabidiol, Jazz) is FDA-approved for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC) in patients 1+ year; Jazz reported Epidiolex 2023 net product sales of approximately $846M. The rare pediatric epilepsy competitive set splits by MOA class. 5HT2B/5HT2C serotonergic: fenfluramine (Fintepla, UCB, acquired from Zogenix) is FDA-approved for DS and LGS and is Epidiolex's most direct rival; generated approximately €360M in 2023 UCB sales with strong growth. GABAergic: clobazam (Onfi, Lundbeck/generic) and stiripentol (Diacomit, Biocodex) are first-line in DS; rufinamide (Banzel, Eisai/generic) is approved for LGS. mTOR inhibitor (TSC-specific direct threat): everolimus (Afinitor, Novartis) is FDA-approved for TSC-associated seizures and subependymal giant cell astrocytomas (SEGA). Sodium channel blockers: cenobamate (Xcopri, SK Life Sciences) is approved for focal-onset seizures (adult); lacosamide (Vimpat, UCB/generic) is approved for focal-onset. Broad-spectrum: valproic acid (Depakote, AbbVie/generic), topiramate (Topamax, J&J/generic), and levetiracetam (Keppra, UCB/generic) are ubiquitous background therapy. Pipeline: soticlestat (TAK-935, Takeda) failed Phase 3 in DS but remains in development. Epidiolex's moat is combined LGS/DS/TSC coverage and differentiated CBD mechanism; Fintepla erosion in DS/LGS is the primary franchise threat.
Dordaviprone (Modeyso, ONC201) received FDA accelerated approval August 2024 for previously treated H3 K27M-mutant diffuse glioma in patients aged 2+ years, becoming the first approved targeted therapy in this ultra-rare pediatric/young-adult CNS malignancy. The competitive set is thin and largely off-label. DRD2 antagonist/ClpP agonist (direct MOA): Modeyso stands alone in approved DRD2/ClpP-targeted therapy. Radiation is the only established standard and is non-curative; temozolomide (Temodar, Merck/generic) is used off-label despite low MGMT-promoter methylation rates in H3 K27M tumors and limited benefit. Bevacizumab (Avastin, Roche/biosimilars) provides symptomatic edema control but no survival benefit. Emerging MOAs include: IDH inhibitor vorasidenib (Voranigo, Servier), FDA-approved August 2024 for IDH1/2-mutant grade 2 glioma — a biologically distinct population (adult, IDH-mutant astrocytoma/oligodendroglioma), but commercial overlap exists in neuro-oncology referral networks and testing/diagnostic pathways. MEK inhibitor: tovorafenib (Ojemda, Day One/Servier, FDA-approved April 2024) targets pediatric BRAF-altered low-grade glioma — adjacent pediatric neuro-oncology franchise. Early-stage: ONC206 (imipridone class sibling) is in Phase 1 for pediatric and adult CNS tumors. H3 K27M prevalence is approximately 500-1,000 new US cases annually; Modeyso's moat is orphan-level exclusivity and MOA uniqueness, with pricing reflective of ultra-rare status.
Jazz Pharmaceuticals completed $1.5B acquisition of Celator, gaining Vyxeos (CPX-351), liposomal daunorubicin/cytarabine for AML.
FDA approved Vyxeos for treatment-related AML and AML with MDS-related changes, establishing new standard of care in high-risk AML.
Vyxeos gained FDA approval and became important AML treatment. $1.5B delivered a commercial product generating meaningful hematology revenue.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Jazz Pharmaceuticals PLC / Celator Pharmaceuticals (this deal) | 2016 | $1.5B | 73 |
| Jazz Pharmaceuticals PLC / GW Pharmaceuticals | 2021 | $7.2B | 77 |
| Jazz Pharmaceuticals PLC / AbCellera Biologics Inc. | 2026 | $848M | 50 |
| Jazz Pharmaceuticals PLC / Actio Biosciences, Inc. | 2026 | $1.3B | — |
| Jazz Pharmaceuticals PLC / Chimerix, Inc. | 2025 | $935M | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
← Browse all deals · How we score deals
More: 2016 deals · Jazz Pharmaceuticals PLC deals · Neurology deals